Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
3 competitors in HIV Infections
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Truvada
Treatment of HIV-1 infection: Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years. Pre-exposure prophylaxis (PrEP): Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
View on EMADiabetic Retinopathy
Osteoporosis
Cardiovascular Disease
Malignant Neoplasms of Male Genital Organs
HPV Positive Oropharyngeal Squamous Cell Carcinoma